Abliva AB (Nasdaq Stockholm: ABLI) welcomes, on the occasion of The World Mitochondrial Disease Week, to its virtual Mitochondria Day 2020, on 16 September at 2 p.m. – 4 p.m. CEST. The purpose of the day is to increase understanding of the enormous medical need within primary mitochondrial diseases, treatments under development, as well as the growing interest in investments in the area.
We begin by taking a closer look at what it’s like to be a patient and a relative, and how health care experts work. Furthermore, representatives from the company will present Abliva’s program in drug development, followed by exciting insights into clinical development and clinical studies with the help of our network of international experts. We conclude the day with a discussion on the views on, and conditions for, investments in projects for the development of medicines for rare diseases.
The program is designed to be of interest both for those who have a professional interest – in health care, research, or the media – as well as for patients, relatives, and the interested public. The Mitochondria Day is part of The World Mitochondrial Disease Week, which runs from 13 to 19 September. https://mitochondrialdiseaseweek.org.
The event is virtual, requires no pre-registration, and can be followed via link (to be sent out shortly). The recording will also be posted afterwards on Abliva’s website, www.abliva.com. Some of the presentations/interviews will be held in Swedish and some in English. During the event you can ask questions via ir@abliva.com.
A warm welcome on 16 September!